News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015
AstraZeneca PLC (AZN)'s Experimental Lung Cancer Drug Delays Disease By More Than a Year 4/17/2015
Cellectar Biosciences  (NVLT) Initiates Proof-Of-Concept Trial Of I-131-CLR1404 In Multiple Myeloma 4/16/2015
Avelas Biosciences Initiates Phase 1b Trial Of AVB-620 In Breast Cancer Patients 4/16/2015
EMD Serono Highlights Scientific Commitment To MS With Data Presented At The American Academy of Neurology Annual Meeting 4/16/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Demcizumab Data From Phase 1b Clinical Trial In Non-Small Cell Lung Cancer Patients At The European Lung Cancer Conference 4/16/2015
Targacept (TRGT) Announces Negative Top-Line Results From Exploratory Study Of TC-6499 In Diabetic Gastroparesis 4/16/2015
Protalex, Inc. (PRTX) Announces Findings From Final Cohort Of U.S. Phase Ib Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 4/16/2015
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma 4/16/2015
PsiOxus Therapeutics Limited Expands Clinical Studies For Immuno-Oncolytic Treatment Following Positive Response To Intravenous Delivery 4/16/2015
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015
SELLAS Life Sciences Group And Trojantec Ltd. Sign Exclusive License Agreement For Global Rights On Development And Commercialization Of Innovative TR-1 Anti-Cancer Antennapedia Technology 4/15/2015
Replicel Life Sciences Receives Approval To Conduct Clinical Trial For Patients With Chronic Achilles Tendinosis 4/15/2015
Hydra Biosciences, Inc. Receives Approval From Health Canada To Begin Phase 1 Trial For HX-100 4/14/2015
Prolong Pharmaceuticals Presents Data On Unique "Un-Sickling" In Vitro Activity Observed In Sickle Cell Investigational Drug SANGUINATE 4/14/2015
InnFocus FDA Phase One Enrollment Reaches 75 Patient Filing Milestone 4/13/2015
Upsher-Smith Laboratories To Present Data Evaluating The Long-Term Safety And Efficacy Of Qudexy XR (Topiramate) Extended-Release Capsules And Alternative Administration Techniques 4/13/2015
Cytori Therapeutics, Inc. (CYTX) Provides Twelve Month Data Update On Scleradec-I Trial 4/13/2015
Suven Life Sciences Ltd Initiated Multiple Ascending Dose (MAD) Studies In Phase 1 Clinical Trial For Their Investigational Compound SUVN-G3031 4/13/2015
Cell MedX Corp. (CMXC) Announces Additional Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 4/13/2015
Cardio3 BioSciences Enrolls First Patient in Phase I Trial For NKG2D CAR T-Cell 4/13/2015
FDA Modifies Partial Clinical Hold On Tekmira (TKMR)'s TKM-Ebola IND To Allow Multiple Dosing Of Healthy Volunteers 4/10/2015
Eisai Company (ESALY.PK) And Arena Pharmaceuticals, Inc. (ARNA) Complete Registrational Trials Of An Extended Release Formulation Of Lorcaserin 4/10/2015
Sihuan Pharmaceutical Starts US Trial Of Novel Cancer Drug 4/10/2015
MedImmune (AZN) Release: MEDI8897 Receives Fast Track Designation By The FDA For The Prevention Of Respiratory Disease Caused By RSV In Infants 4/9/2015
VBI Vaccines Announces New Data Supporting The Manufacture Of Its Prophylactic CMV Vaccine Candidate 4/9/2015
Advaxis, Inc. And Merck & Co. (MRK) Announce Initiation Of Enrollment In The Phase I/II Study Of ADXS-PSA In Combination With Anti-PD-1 Therapy, KEYTRUDA (Pembrolizumab), For The Treatment Of Advanced Prostate Cancer 4/8/2015
Prolong Pharmaceuticals' Flagship Product SANGUINATE Granted Orphan Drug Designation By The FDA 4/8/2015
Benitec, Inc. (BLT.AX) Provides Update On TT-034 Trial 4/7/2015
Targacept (TRGT) Abandons Nictoine Focus for Alzheimer's 4/6/2015
Celldex (CLDX) Announces Initiation Of Phase 1/2 Study Of Varlilumab In Combination With Ipilimumab And CDX-1401 In Metastatic Melanoma 4/6/2015
Curis, Inc. (CRIS) Announces Orphan Drug Designation For CUDC-907 In Diffuse Large B-Cell Lymphoma 4/6/2015
Immunomedics, Inc. (IMMU) To Provide Update On Sacituzumab Govitecan For The Therapy Of Solid Cancers 4/6/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Luye Pharma Reports Successful Phase I Trials Of Novel Anti-depressant 4/2/2015
Immune Design Corporation (IMDZ) Announces Positive Topline Data From Three Phase 1 Clinical Trials Of Immuno-Oncology Agents 4/1/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015
Idera Pharmaceuticals, Inc. (IDRA) Announces FDA Orphan Drug Designation For IMO-8400 For The Treatment Of Diffuse Large B-Cell Lymphoma 4/1/2015
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015
Portage Biotech's Biohaven Announces Agreement With inVentiv Health (VTIV) 4/1/2015
Oramed Pharmaceuticals Inc. (ORMP) Enrolls First Patient In Its Glucose Clamp Study For Oral Insulin 4/1/2015
Dyax Corp. (DYAX) Announces Positive Results From Phase Ib Clinical Trial Of DX-2930 4/1/2015
Vaccinex, Inc. Provides An Update On Its VX15/2503 Phase 1 Clinical Trial In Multiple Sclerosis Patients 3/31/2015
Lion Biotechnologies, Inc. Announces Positive Data From A TIL-Ipilimumab Combination Study In Melanoma 3/30/2015
Matinas BioPharma Completes Enrollment In First Human Trial Of MAT9001 3/30/2015
Novavax, Inc. (NVAX) Presents New Data From Non-Human Primate Ebola Challenge At The 7th International Symposium On Filoviruses 3/30/2015
DURECT Corporation (DRRX) Announces Initiation Of DUR-928 Multi-Dose Phase 1 Study 3/30/2015
PRA Health Sciences Expands Global Phase I Patient Strategy 3/30/2015
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015
PledPharma Presents Top-Line Results From Its PhaseIIb Study - Pledox(R) Reduces Nerve Damage In Conjunction With Chemotherapy By 43 Percent 3/30/2015
Calithera Biosciences, Inc. (CALA) Reports Fourth Quarter And Full Year 2014 Financial Results And Recent Highlights 3/27/2015
New Research Throws Cold Water on Biogen (BIIB)'s Recent Breakthrough 3/26/2015
Aridis Pharmaceuticals Commences Phase 1 Clinical Study Of Aerucin Monoclonal Antibody For Acute Pneumonia 3/26/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results From Phase 1 AME & Renal Clearance Clinical Studies Of Neuropsychiatric Drug Candidate ELND005 3/26/2015
Essentialis Presents Results From The First Phase Of Clinical Study PC025 Evaluating DCCR In The Treatment Of Prader-Willi Syndrome At ACMG Annual Clinical Genetic Meeting 3/26/2015
Immune Design Corporation (IMDZ) Announces Treatment Of Patients With CMB305 Investigational Immuno-Oncology Agent 3/26/2015
Tianjin CanSino Biotechnology Release: China Ebola Vaccine Passes Phase I Test 3/26/2015
Zogenix (ZGNX) Announces First Patient Dosed In Relday Multi-Dose Clinical Study 3/26/2015
Vical Incorporated (VICL) Expands Infectious Disease Portfolio With Novel Antifungal From Astellas Pharma Inc. (ALPMY) 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Aduro Biotech Receives Orphan Drug Designation For CRS-207 In Mesothelioma 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Biogen (BIIB) Alzheimer's Drug Aducanumab Exceeds Expectations 3/25/2015
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Phase I Results From CAR-T Immuno-Oncology Clinical Development Programs 3/25/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302 3/25/2015
BioLineRx Ltd. Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment 3/25/2015
Tenth Cohort Completed In Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin, No Adverse Events Reported 3/25/2015
Prothena (PRTA) Soars on Positive Phase I Results Of Parkinson's Drug PRX002 3/24/2015
Biogen (BIIB) Drops Idec From Corporate Name, Expands Ambitions in Alzheimer's, ALS 3/24/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence First Clinical Study For Novel Oral Formulations Of Buprenorphine 3/24/2015
GenVec Inc. (GNVC) Reports Fourth Quarter And 2014 Year-End Financial Results 3/24/2015
Eli Lilly (LLY),Novartis AG (NVS)-Backed Startup, Aeglea, Nabs $44 Million 3/23/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
Biogen (BIIB) Slides For Alzheimer's Drug Wow Analysts, Set Up Fight for Eli Lilly (LLY) 3/23/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data on Isis-ANGPTL3Rx 3/23/2015
GenVec Inc. (GNVC) And TheraBiologics Form Collaboration To Develop Neural Stem Cell Mediated Cancer Therapies 3/23/2015
AB Science (AB.PA): Masitinib Receives Orphan Drug Designation For Amyotrophic Lateral Sclerosis From FDA 3/23/2015
Kamada Ltd. (KMDA) Awarded European Orphan Drug Designation For Its Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease 3/23/2015
Alzheon Announces Phase 1 Results Of ALZ-801, A First-in-Class Inhibitor Of Amyloid Formation And Neurotoxicity For Alzheimer’s Disease 3/20/2015
Biogen Idec (BIIB) Presents Positive Interim Results From Phase 1B Study Of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) At 2015 AD/PD Conference 3/20/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Pharmacokinetics Data From Phase 1a And 1b Trials Of SYN-004 To Protect The Microbiome And Prevent C. difficile Infection 3/19/2015
HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan 3/19/2015
Advaxis, Inc. Announces First Patient Treated In Phase 1/2 Dose-Escalation Study Of ADXS-HPV For Recurrent Cervical Cancer 3/19/2015
John Theurer Cancer Center Joins Study Exploring Novel Delivery Of Cancer-Selective Gene Therapy To Treat Brain Cancer 3/19/2015
Neurotensin, Vectorised By Vect-Horus, Is The First Drug-Candidate In Neuroprotective Hypothermia 3/19/2015
Heron Therapeutics, Inc. (APPA) Reports Positive Results From Phase 1 Study Of HTX-011 3/19/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
Expectations are High as Biogen Idec (BIIB) Prepares to Reveal Alzheimer's Data 3/18/2015
Lixte Biotechnology Completes Private Placement Of Convertible Preferred Stock 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Relmada Therapeutics Reports Positive Phase 1 Results For NMDA Receptor Antagonist D-Methadone 3/17/2015
Zai Lab Begins Trial Of Novel Respiratory Disease Drug 3/17/2015
GliaCure Receives $1 Million Grant For Phase 1b Alzheimer's Clinical Trial 3/17/2015
Advaxis, Inc. Presents Preliminary Data From A Phase I/II Trial Of ADXS-HPV In HPV-Associated Anal Cancer In Combination With Chemoradiation Showing Complete Response And No Recurrences To Date In All Treated Patientsa 3/16/2015
PharmaCyte Biotech (NVLX) Provides Update On Corporate Developments And Progress With Cancer And Diabetes Programs 3/16/2015
VAXIL Receives EU Orphan Drug Designation For Immucin For The Treatment Of Multiple Myeloma 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
NeuralStem Inc. Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results 3/16/2015
Cleveland Biolabs Inc. (CBLI) Announces Completion Of Dosing In Phase I Study Of CBLB612 In Russian Federation 3/16/2015
ASLAN Reports Positive Phase I Results From Cancer Drug 3/16/2015
Rock Creek Pharmaceuticals Files 2014 Annual Report And Provides Clinical Development Update 3/13/2015
Dr. Falk Pharma And Zedira Enter Phase I Clinical Trials For A Celiac Disease Drug 3/13/2015
Annias Immunotherapeutics, Inc. Release: Dramatic Patient Survival Benefit Shown For New Approach To Treating Glioblastoma Multiforme Licensed To Annias Immunotherapeutics 3/12/2015
TiGenix Completes Treatment In Phase I Sepsis Challenge Trial With Cx611 3/12/2015
Protalex, Inc. (PRTX) Initiates Enrollment Of Phase I/II Continuation Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 3/12/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of Its Novel Anemia Therapeutic TBI 304H 3/12/2015
Concert Pharmaceuticals, Inc. (CNCE) Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor For Cystic Fibrosis 3/12/2015
Lpath, Inc. (LPTN) To Submit Additional Data For Lpathomab Investigational New Drug Application 3/11/2015
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial 3/11/2015
Soligenix (SNGX) Announces Publication Of Successful Preclinical Efficacy And Immunogenicity Results For Ricin Toxin Vaccine 3/11/2015
Dr. Anita J. Chawla Joins CytRx Corporation (CYTR) Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology 3/11/2015
Antibe Therapeutics Inc. (ATE.V) Provides An Update On Its Data Review And Corporate Strategy 3/11/2015
MorEx Moves To Intent-to-Cure Stage Of MTL-005 Radiation Enhancer Head & Neck Cancer Phase 1 Trial 3/11/2015
PacificGMP And ArmaGen Technologies, Inc. Announce Successful Manufacture Of Armagen's Investigational Enzyme Replacement Therapies, AGT-182 And AGT-181, For Phase 1 Clinical Trial 3/10/2015
Halozyme Therapeutics, Inc. (HALO) Reports Selection Of First Product Candidate Under Janssen Biotech Inc. (JNJ) Collaboration 3/10/2015
Innate Pharma (IPH.PA ) Collaborates With NCIC Clinical Trials Group On The Phase I/II Trial Of IPH2201 In Ovarian Cancer 3/9/2015
Emergent BioSolutions (EBS) And MorphoSys AG Initiate Phase 1 Clinical Study To Evaluate The Novel Oncology Immunotherapeutic MOR209/ES414 For Prostate Cancer 3/9/2015
Heat Biologics Receives U.S. FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer 3/9/2015
Versartis, Inc. (VSAR) Presents 12-Month Data For VRS-317 At Late-Breaker Session At Endocrine Society's Annual Meeting 3/9/2015
ORYX Successfully Completes Phase 1/2a Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers 3/9/2015
Targovax To Expand On-Going Phase I/II CT-TG01-01 Pancreatic Cancer Study With A New Group Of Up To 13 Patients 3/9/2015
XOMA (US) LLC (XOMA) Presents Positive Phase I XOMA 358 Data At The ENDO Meeting 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
XOMA (US) LLC (XOMA) Will Present XOMA 358 Phase 1 Data At ENDO 2015 3/6/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/6/2015
Asterias Biotherapeutics Initiates Patient Enrollment For Phase 1/2a Clinical Trial Of AST-OPC1 In Newly Injured People With Complete Cervical Spinal Cord Injury 3/5/2015
Ironwood Pharmaceuticals (IRWD) Initiates Phase I Clinical Study Of sGC Stimulator IW-1973 3/5/2015
Molecular Templates Inc. Announces Start Of Phase 1 Clinical Trial Of MT-3724 In Refractory Non-Hodgkin’s Lymphoma 3/5/2015
Eisai Company, Ltd. (ESALY.PK) And Merck & Co. (MRK) Enter Collaboration To Explore Novel Combination Regimens Of Anti-PD-1 Therapy With Multi-Targeting RTK Inhibitor And Microtubule Dynamics Inhibitor In Multiple Types Of Cancer 3/5/2015
Symbiomix Therapeutics, LLC Studies Show Drug Candidate For Women's Health Infections Is Safe And Well-Tolerated 3/4/2015
Immunomic Therapeutics Explains Proprietary LAMP-vax Platform In Nature Advertorial Supplement 3/4/2015
Aerpio Announces Publication Of Positive Results Of Phase 1b/2a Clinical Trial Of Novel Tie2 Activator, AKB-9778, For The Treatment Of Patients With Diabetic Macular Edema (DME) – TIME-1 Study 3/4/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Dry Powder Inhaler Product 3/3/2015
Pulmokine Receives $1 Million Investment From Broadview Ventures To Advance PAH Candidate Into First Clinical Trial 3/3/2015
Islet Sciences Enters Into Exclusive License Agreement For Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate 3/3/2015
DURECT Corporation (DRRX) Announces Epigenomic Regulator Program Including A New NAFLD/NASH And Acute Organ Injury Product Candidate In Development 3/3/2015
MyoKardia Announces Initiation Of Phase 1 Clinical Study Of MYK-461 For Hypertrophic Cardiomyopathy 3/3/2015
Cerulean Pharma Inc. (CERU) Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer 3/3/2015
Epizyme (EPZM) Announces Presentation Of Data From Phase 1 Study Of EZH2 Inhibitor EPZ-6438 (E7438) 3/3/2015
Clinical Study Published In Neurology Finds That electroCore’s Non-Invasive Vagus Nerve Stimulation Is Effective In Treating Cluster Headaches 3/3/2015
Rutgers Cancer Institute Of New Jersey Starts ONC201 Clinical Trials 3/3/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Cancer Of The Fallopian Tube 3/2/2015
TRACON Pharmaceuticals, Inc. (TCON) Announces Positive Phase 1b Results For TRC105 In Combination With Inlyta (Axitinib) At The ASCO 2015 Genitourinary Cancers Symposium 3/2/2015
Almac Discovery Initiates Phase 1 Study Of ALM201 For The Treatment Of Patients With Advanced Ovarian Cancer And Other Solid Tumours 3/2/2015
Boehringer Ingelheim Puts Hold on Key Alzheimer's Drug Trial 3/2/2015
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc. (VTAE) Release: BACE Inhibitor BI 1181181 Voluntarily Put On Temporary Clinical Hold For Safety Evaluation 2/27/2015
INSYS Therapeutics Announces Its Pharmaceutical Cannabidiol Received Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 2/27/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
Sangamo BioSciences (SGMO) Presents New Clinical Data At CROI 2015 From Trial Of ZFP Therapeutic Designed To Provide Functional Control Of HIV 2/26/2015
ObsEva Reports Positive Phase 1 Results For The First Orally Active Oxytocin Antagonist OBE001 To Treat Preterm Labour 2/26/2015
Innocrin Pharmaceuticals Inc. To Present Interim Results From Its Phase 1/2 Prostate Cancer Clinical Study And Preclinical Results That Demonstrate VT-464 Efficacy In A Clinically-Relevant Enzalutamide-Resistant Mouse Model 2/26/2015
Ampio Pharmaceuticals, Inc. (AMPE) Announces Top-Line Results Of The Double-Blind Multiple Intra-Articular Injections (STRUT) Study Of Ampion In Patients With Moderate To Severe Osteoarthritis Of The Knee 2/25/2015
Anavex (AVXL) Release: ANAVEX 2-73 Could Prevent Alzheimer's Disease In Addition To Modifying And Treating Symptoms 2/25/2015
Cell MedX Corp. (CMXC) Announces Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 2/25/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Beclomethasone Dipropionate HFA Product 2/24/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions In Prekallikrein Levels 2/24/2015
Bavarian Nordic (BAVA.CO) Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium 2/24/2015
BioTime (BTX) Announces First Patient Treated In Pivotal Clinical Trial Of Renevia™ For HIV-Associated Lipoatrophy 2/24/2015
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015
Arrowhead Research Corporation (ARWR) Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency 2/23/2015
ReveraGen BioPharma Announces Start Of Phase 1 Clinical Trial Of VBP15 Dissociative Steroid Drug 2/18/2015
Dipexium Pharmaceuticals (DPRX) Announces Successful Completion And Initial Results Of Phase 1 Skin Sensitization Trial Of Locilex 2/17/2015
Helix Biopharma (TSX:HBP) Initiates Enrollment for Eleventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 2/17/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Treatment Shows Efficacy And Tolerability In Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant 2/17/2015
Stealth Biotherapeutics Initiates A Clinical Study Of Bendavia For The Treatment Of Orphan Mitochondrial Diseases 2/17/2015
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Colorectal Cancer 2/17/2015
Anaheim Clinical Trials (ACT) ‘Slam Dunks’ Enrollment On Another Japanese Bridging Study 2/16/2015
Galapagos NV (GLPG.BR) Reports Positive Phase 1 Results For GLPG1690 2/16/2015
Bexion Pharmaceuticals Receives Orphan Drug Designation For Saposin C, The Active Ingredient In BXQ-350 For Glioblastoma Multiforme From FDA 2/16/2015
Soligenix (SNGX) Release: Ricin Toxin Vaccine Poster Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC 2/13/2015
Genzyme (GENZ) Presents Data From Its Phase 1b Program For Niemann-Pick Type B At The Lysosomal Disease Network’s WORLD Symposium 2015 2/13/2015
Novavax, Inc. (NVAX) Announces Initiation Of Ebola Vaccine Phase 1 Clinical Trial Supported By Non-Human Primate Challenge Data And Documented Rapid Manufacturing Capabilities 2/12/2015
Oncobiologics Inc. Announces ONS-3010 (Humira/Adalimumab Biosimilar) Meets Primary Endpoints In First Clinical Study 2/12/2015
Aileron Therapeutics Initiates Phase 1 Cancer Study Of ALRN-6924 In Advanced Hematologic And Solid Malignancies With Wild Type P53 2/12/2015
Verastem, Inc. (VSTM) Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma 2/12/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Meets Primary Endpoint In First Human Clinical Study 2/11/2015
Immune Design Corporation (IMDZ) Announces First Patients Dosed In Phase 1 Clinical Trial Of G100 Investigational Immuno-Oncology Agent 2/11/2015
Ultragenyx Pharmaceuticals (RARE) Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7 2/11/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
Edge Therapeutics Reports Initial Data From Its Phase 1/2 NEWTON Trial For EG-1962 For Improvement Of Outcomes After Ruptured Brain Aneurysm 2/11/2015
Heron Therapeutics, Inc. (APPA) Initiates Phase 1 Clinical Study Of HTX-011 For The Treatment Of Post-Operative Pain 2/11/2015
Theravance Biopharma Initiates Patient Registry Study For VIBATIV(R) (telavancin) 2/11/2015
BIOCEO15: ContraFect (CFRXU) CEO Says Lysin, AB Anti-Infectives Are “Game-Changers” in 2015 2/10/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From Phase 1b Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile Infection 2/10/2015
Apellis Pharmaceuticals Enters Clinical Testing Phase In Its Age-Related Macular Degeneration Program 2/10/2015
Strategic Science & Technologies Initiates Phase 1 Study To Evaluate Topical Sildenafil In Women With Female Sexual Arousal Disorder 2/9/2015
Alkermes plc (ALKS) Announces Positive Topline Results From Phase 1 Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 2/9/2015
Trevena, Inc. (TRVN) Announces Positive Results From Phase 1 Multiple Ascending Dose Study Of TRV734 For Moderate To Severe Acute And Chronic Pain 2/9/2015
Safety And Preliminary Efficacy Of Human Neural Stem Cells In StemCells (STEM)'s Dry AMD Study To Be Presented At Ophthalmology Conference 2/5/2015
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Non-Small Cell Lung Cancer 2/5/2015
THERAVECTYS Obtains Orphan Drug Designation From European Medicines Agency For Its Lentiviral Vector-Based Therapeutic Vaccine Against Adult T-Cell Leukemia And Lymphoma 2/5/2015
Proteostasis Therapeutics, Inc. Announces A New Class Of Agents For Cystic Fibrosis Called CFTR Amplifiers And Selects PTI130 As A Development Candidate 2/5/2015
Akaal Pharma Announces Positive Results From Phase 1 Clinical Study Of Novel Topical AKP-11 For The Treatment Of Psoriasis 2/5/2015
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus FOLFOX In Advanced Gastrointestinal Malignancies 2/3/2015
bluebird bio (BLUE)'s Rare Blood Disorder Drug Tagged a Breakthrough by the FDA 2/3/2015



//-->